CL2017001118A1 - Receptores quimericos de antígeno anti–cldn y métodos de uso - Google Patents

Receptores quimericos de antígeno anti–cldn y métodos de uso

Info

Publication number
CL2017001118A1
CL2017001118A1 CL2017001118A CL2017001118A CL2017001118A1 CL 2017001118 A1 CL2017001118 A1 CL 2017001118A1 CL 2017001118 A CL2017001118 A CL 2017001118A CL 2017001118 A CL2017001118 A CL 2017001118A CL 2017001118 A1 CL2017001118 A1 CL 2017001118A1
Authority
CL
Chile
Prior art keywords
methods
chimeric receptors
cldn
antigen chimeric
cldn antigen
Prior art date
Application number
CL2017001118A
Other languages
English (en)
Inventor
David Liu
Paul Anthony Escarpe
Scott J Dylla
Robert A Stull
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/064165 external-priority patent/WO2015069794A2/en
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of CL2017001118A1 publication Critical patent/CL2017001118A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>EN LA PRESENTE SE PROPORCIONAN NUEVOS RECEPTORES QUIMÉRICOS DE ANTÍGENO ANTI–CLDN Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR TRASTORNOS PROLIFERATIVOS.</p>
CL2017001118A 2014-11-05 2017-05-05 Receptores quimericos de antígeno anti–cldn y métodos de uso CL2017001118A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2014/064165 WO2015069794A2 (en) 2013-11-06 2014-11-05 Novel anti-claudin antibodies and methods of use
US201562157928P 2015-05-06 2015-05-06
US201562247108P 2015-10-27 2015-10-27

Publications (1)

Publication Number Publication Date
CL2017001118A1 true CL2017001118A1 (es) 2018-01-05

Family

ID=55909771

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001118A CL2017001118A1 (es) 2014-11-05 2017-05-05 Receptores quimericos de antígeno anti–cldn y métodos de uso

Country Status (23)

Country Link
US (1) US20170334991A1 (es)
EP (1) EP3215523A4 (es)
JP (1) JP2017535283A (es)
KR (1) KR20170085531A (es)
CN (1) CN107207580A (es)
AU (1) AU2015343079A1 (es)
BR (1) BR112017009517A2 (es)
CA (1) CA2966618A1 (es)
CL (1) CL2017001118A1 (es)
CO (1) CO2017005538A2 (es)
CR (1) CR20170235A (es)
DO (1) DOP2017000110A (es)
EA (1) EA201790967A1 (es)
EC (1) ECSP17031725A (es)
IL (1) IL252090A0 (es)
MA (1) MA40921A (es)
MX (1) MX2017005797A (es)
PE (1) PE20171060A1 (es)
PH (1) PH12017500825A1 (es)
SG (1) SG11201703669YA (es)
TW (1) TW201625677A (es)
WO (1) WO2016073649A1 (es)
ZA (1) ZA201703471B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928671A1 (en) * 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
WO2018071792A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
BR112020004126A2 (pt) 2017-09-29 2020-09-08 Daiichi Sankyo Company, Limited conjugado anticorpo-derivado de pirrolbenzodiazepina
US20230158071A1 (en) * 2018-12-07 2023-05-25 Crage Medical Co., Limited Tumor combined immunotherapy
WO2020143631A1 (zh) * 2019-01-07 2020-07-16 科济生物医药（上海）有限公司 细胞免疫治疗的组合
US20210347847A1 (en) * 2020-05-11 2021-11-11 The Broad Institute, Inc. Therapeutic targeting of malignant cells using tumor markers
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CA3212530A1 (en) * 2021-03-05 2022-09-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用
WO2024088325A1 (zh) * 2022-10-25 2024-05-02 科济生物医药（上海）有限公司 抗体及其应用
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
JP5374360B2 (ja) * 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
EP4282428A3 (en) * 2008-01-11 2024-03-20 The University of Tokyo Anti-cldn6 antibody
EP2499161B8 (en) * 2009-11-11 2017-10-25 Ganymed Pharmaceuticals GmbH Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3623380A1 (en) * 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2928671A1 (en) * 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
CN113150109A (zh) * 2014-04-01 2021-07-23 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
JP2019500335A (ja) * 2015-12-04 2019-01-10 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗クローディン抗体及び使用方法

Also Published As

Publication number Publication date
US20170334991A1 (en) 2017-11-23
EA201790967A1 (ru) 2017-10-31
MX2017005797A (es) 2017-10-23
TW201625677A (zh) 2016-07-16
BR112017009517A2 (pt) 2017-12-19
MA40921A (fr) 2017-09-12
PH12017500825A1 (en) 2017-10-18
JP2017535283A (ja) 2017-11-30
ZA201703471B (en) 2019-06-26
CA2966618A1 (en) 2016-05-12
WO2016073649A1 (en) 2016-05-12
ECSP17031725A (es) 2017-06-30
EP3215523A4 (en) 2018-06-20
CR20170235A (es) 2017-07-21
DOP2017000110A (es) 2017-05-31
CN107207580A (zh) 2017-09-26
IL252090A0 (en) 2017-07-31
EP3215523A1 (en) 2017-09-13
SG11201703669YA (en) 2017-06-29
CO2017005538A2 (es) 2017-10-10
KR20170085531A (ko) 2017-07-24
PE20171060A1 (es) 2017-07-21
AU2015343079A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
CL2017001118A1 (es) Receptores quimericos de antígeno anti–cldn y métodos de uso
CO2017008804A2 (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
PE20181005A1 (es) Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
PE20231655A1 (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
CL2018001481A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
ES2969968T3 (es) Uso de anticuerpos anti-CD40 para tratamiento de nefritis lúpica